Production issues could put a damper on Novo Nordisk's 2022

Novo Nordisk’s supply issues of its obesity drug, Wegovy, are blurring the company’s growth outlook and creating doubts about its 2022 guidance, reports Danish media Børsen.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Analysts and investors are concerned about Novo Nordisk’s current production problems with obesity drug Wegovy, which have arisen due to issues at the Danish pharmaceutical company’s contract manufacturer, Catalent, reports Danish business media Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading